Clinical Scorecard: Molecular Factors Associated With Minimal Residual Disease in Newly Diagnosed Multiple Myeloma After Quadruplet Therapy
At a Glance
Category
Detail
Condition
Newly diagnosed multiple myeloma (NDMM), a genetically and clinically heterogeneous plasma-cell malignancy.
Key Mechanisms
The study profiles genomic alterations, gene expression, and DNA methylation. The article describes APOBEC-mediated mutagenesis and chromothripsis as genomic-instability processes enriched in high-risk disease.
Target Population
Patients with NDMM in the MIDAS phase 3 trial; molecular characterization included 423 screened cases, while MRD-predictor analyses were restricted to enrolled patients with available MRD data.
Care Setting
Ancillary study of the MIDAS phase 3 trial, which evaluated MRD-guided consolidation and maintenance approaches after standardized Isa-KRd induction.
Key Highlights
Integrated whole-genome sequencing, RNA sequencing, and DNA methylation profiling was performed in 423 MIDAS cases.
Gene-expression classification identified eight molecular groups associated with genomic alterations.
Among 394 enrolled patients, 368 had post-induction MRD data available.
Guideline-Based Recommendations
Diagnosis
The study used whole-genome sequencing, RNA sequencing, and whole-genome enzymatic methylation sequencing to characterize molecular features.
MRD was determined by deep sequencing or flow cytometry.
Management
The MIDAS trial evaluated consolidation and maintenance approaches guided by MRD status after Isa-KRd induction.
The article describes quadruplet combinations containing an anti-CD38 antibody, a proteasome inhibitor, an immunomodulatory drug, and dexamethasone as the standard induction regimen for NDMM.
Monitoring & Follow-up
MRD was assessed after induction; the article describes MRD as a sensitive treatment-response indicator and an early endpoint associated with progression-free and overall survival in NDMM.
Risks
The article describes APOBEC-mediated mutagenesis and chromothripsis as genomic-instability processes enriched in high-risk disease.
Patient & Prescribing Data
MIDAS molecular characterization included 423 screened patients with NDMM; 394 were enrolled, and 368 had post-induction MRD data.
Patients received standardized Isa-KRd induction. The provided excerpt does not report post-induction MRD rates or expression-group comparisons.
Clinical Best Practices
The molecular characterization cohort comprised 423 screened patients; MRD-predictor analyses were restricted to enrolled patients with available MRD data.
Interpret findings in the context of the MIDAS cohort, which received standardized Isa-KRd induction.
by Florence Magrangeas, Mia Cherkaoui, Victor Bessonneau-Gaborit, Jennifer Derrien, Céline Chevalier, Catherine Guérin-Charbonnel, Benjamin Diamond, Mehmet Kemal Samur, Cyrille Hulin, Denis Caillot, Lionel Karlin, Bertrand Arnulf, Ola Landgren, Nikhil C. Munshi, Hervé Avet-Loiseau, Ludovic Martinet, Jill Corre, Aurore Perrot, Philippe Moreau, Cyrille Touzeau, Stéphane Minvielle, Eric Letouzé
Harold Burstein, MD, PhD, and Rachel Freedman, MD, MPH discuss the results of a new study looking at the impact of food access and poverty on patients with metastatic breast cancer. They also discuss the new Dana-Farber food pantry and patient navigators who help coordinate care.
